Navigation Links
Global Small Molecule Kinase Inhibitors Market to Reach $16.2 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.
Date:6/30/2009

GIA announces the release of a comprehensive global report on Small Molecule Kinase Inhibitors market. World market for small molecule kinase inhibitor drugs is projected to reach $16.2 billion by the year 2015. This is primarily driven by the rising interest over the potential of kinase inhibitors in effectively blocking, and modifying protein kinase triggered tumor cell metabolism, proliferation, and DNA damage. Strong growth in the future will be led by expansion of treatment indications in both oncology, and non-oncology disease areas.

San Jose, CA (PRWEB) June 30, 2009 -- With over 500 identified types of kinase proteins in the human body, its little surprise that these enzymes continue to remain important drug targets for major pharmaceutical drug developers, especially in the oncology space. Given their role in effectively disrupting cell signal pathways, kinase inhibitors are of special interest in the treatment of cancer. The unprecedented success witnessed in patient outcomes with the use of currently commercialized kinase inhibitors, such as, imatinib, among others, has ignited excitement over the untapped potential of this very potent class of drugs. Rising incidences of cancer, and the yet unmet treatment needs offer a strong business case for kinase inhibitors.    

The upcoming years are forecast to witness both the strong growth for multi-targeted kinase inhibitors, and the rising popularity of combination drug therapies. Growing incidences of tumor cell resistance to single targeted kinase inhibitor drugs is fingered as the key reason triggering interest in both combination drug therapies, and multi-targeted kinase inhibitors. For instance, growing incidences of resistance to Gleevec, has turned the spotlight on Nexavar, and Sutent, given the potential of these new drugs to offer the much awaited solution to the treatment impasse hitherto encountered. The multi-targeted kinase inhibitors market is expected to benefit from the growing acceptance of the undisputable fact that the battle against cancer can be horned not by blocking out tumor cells at one point, but by simultaneously blocking multiple biological triggers and pathways, given the tendency of these cells to regroup to recalibrate and spread through new growth paths.

Global sales of Gleevec are projected to steadily increase between the period 2010 and 2015, as stated by the new market research report. New generation kinase inhibitor drugs like Nexavar are forecast to witness robust growth over the period 2006 through 2015.

Leading players operating in the marketplace include Amgen Inc, Novartis, AstraZeneca plc, Genentech, Roche, OSI Pharmaceuticals, Pfizer, Bristol-Myers Squibb, Glaxo SmithKline, Wyeth, Onyx Pharmaceuticals Inc., Merck & Co. Inc, KAI Pharmaceuticals Inc, Celgene Corporation, Sanofi-Aventis, and Bayer Schering Pharma AG, among others.

The report titled "Small Molecule Kinase Inhibitors: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of industry overview, technology, trends, growth drivers, challenges, and most promising drugs in pipeline. Also provided are profiles of major players, and an enumeration of recent developments, mergers, acquisitions, and other strategic industry activities. Global small molecule kinase inhibitors market is analyzed by sales in US$ billion of major drug brands, such as, Gleevec/Glivec, Tarceva, Sutent, Nexavar, Sprycel, Iressa, and Tykerb/Tyverb, among others.

For more details about this comprehensive market research report, please visit - http://www.strategyr.com/Small_Molecule_Kinase_Inhibitors_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press (at) StrategyR (dot) com
Web Site http://www.StrategyR.com/

###

Read the full story at http://www.prweb.com/releases/small_molecule/kinase_inhibitors/prweb2559784.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Global Prescription Drugs Market to Cross $897 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
2. Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes
3. BioStorage Technologies, Inc., Appoints Jeff Goddard to Global Head of Sales
4. Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
5. deCODE Reinstated to Nasdaq Global Market
6. BIO Ventures for Global Health Announces Management Changes
7. World Nanomedicine Market to Cross $160 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
8. Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita-based Center of Excellence with Global Convenience(TM)
9. Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels
10. BD and FIND Achieve Milestone in Global Battle Against MDR-TB
11. Springborn Deploys eStudy(TM) Hosted Solution for Management of Global Environmental Testing
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Global Small Molecule Kinase Inhibitors Market to Reach $16.2 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.
(Date:12/2/2016)... (PRWEB) , ... December 02, ... ... (ETC), a consortium of pharmaceutical and biotechnology companies dedicated to collaboratively developing ... companies interested in supplying a vendor-supported, portable online UHPLC, with robust, probe-based ...
(Date:12/2/2016)... , December 2, 2016 The ... 2021, growing at a CAGR of 7.3% during the forecast period ... hospitals and diagnostic laboratories segment accounted for the largest share of ... ... report on global immunohistochemistry (IHC) market spread across 225 pages, profiling ...
(Date:11/30/2016)... 30, 2016  GenomOncology today announced the appointment of ... Affairs.  Dr. Coleman will oversee clinical content ... knowledge-enabled platform. The GenomOncology software suite empowers molecular pathologists with ... and clinical decision support, from quality control through reporting. ... , , ...
(Date:11/30/2016)... 2016 Biotest Pharmaceuticals Corporation (BPC), a leading ... the addition of its newest plasma collection center located ... . The 15,200 square foot state-of-the-art facility officially opened ... brings the total number of BPC,s plasma collection centers ... BPC,s Chief Executive Officer said "We are pleased to ...
Breaking Biology Technology:
(Date:11/24/2016)... -- Cercacor today introduced Ember TM Sport Premium ... measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion Index, ... approximately 30 seconds. Smaller than a smartphone, using only ... key data about their bodies to help monitor these ... Hemoglobin carries oxygen to muscles. When hemoglobin and ...
(Date:11/19/2016)... Securus Technologies, a leading provider of civil ... corrections and monitoring, announced today that it has offered ... an independent technology judge determine who has the largest ... telephone calling platform, and the best customer service. ... of what we do – which clearly is not ...
(Date:11/15/2016)... ROCKVILLE, Md. , Nov. 15, 2016 /PRNewswire/ ... clinical company developing therapeutics focused on the gut ... public offering of 25,000,000 shares of its common ... its common stock at a price to the ... gross proceeds to Synthetic Biologics from the offering, ...
Breaking Biology News(10 mins):